Strategic Report on Angiotensin Receptor Blockers (ARBs) Market: Growth Opportunities and Emerging Challenges
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Will the Angiotensin Receptor Blockers (ARBs) Market Evolve in Terms of Growth and Size by 2029?
In recent times, the market size of angiotensin receptor blockers (arbs) has been on a steady increase. Estimates see it rising from $8.51 billion in 2024 to $8.78 billion in 2025 with a compound annual growth rate (CAGR) of 3.1%. Factors such as an increase in hypertension cases, clinical efficacy, the burden of cardiovascular disease, renal protection, clinical guidelines, and the use of ARBs as first-line treatment, coupled with their cost-effectiveness, account for the growth during the historic period.
The market for angiotensin receptor blockers (arbs) is slated to experience a consistent rise in the coming years, with projections suggesting it will attain a valuation of “$10.52 billion in 2029, growing at a compound annual growth rate (CAGR) of 4.6%.” Factors contributing to this uptick include precision medicine tactics, a focus on amalgamated treatments, wider worldwide market reach, treatment avenues based on biomarkers, governmental programs, and increased hypertension awareness. The forecast period will also see prevailing trends including the adoption of telemedicine, increase in research and development expenditures, intensifying generic competition and patent expirations, digitization of medication adherence solutions, and competition from biosimilars.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp
What factors are expected to fuel Angiotensin Receptor Blockers (ARBs) market growth in the coming years?
The angiotensin receptor blockers market is poised for growth, propelled by the rising incidences of cardiovascular ailments. Cardiovascular disease (CVD) encompasses any conditions which impact the heart or blood vessels and is frequently linked with the buildup of fatty deposits in the arteries (atherosclerosis) and an elevated risk of blood clots. The function of angiotensin receptor blockers is to reduce blood pressure and enhance the ability of the heart to pump blood by aiding in the relaxation of arteries and veins, subsequently reducing the risk of cardiovascular disease. As per the American College of Cardiology, a professional medical organization based in the US, indications show a significant predicted increase in cardiovascular risk factors and disease prevalence by 2060 in the country. Therefore, the escalating occurrence of cardiovascular diseases is a driving factor for the expansion of the angiotensin receptor blockers market.
What Are The Key Findings From The Segmentation Analysis Of The Angiotensin Receptor Blockers (ARBs) Market?
The angiotensin receptor blockers (arbs) market covered in this report is segmented –
1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Valsartan: Tablets, Capsules, Injectable Forms
2) By Telmisartan: Tablets, Capsules
3) By Losartan: Tablets, Oral Solution
4) By Irbesartan: Tablets, Oral Solution
5) By Azilsartan: Tablets
6) By Olmesartan: Tablets, Oral Suspension
How Are Key Trends Driving Expansion In The Angiotensin Receptor Blockers (ARBs) Industry?
Leading companies in the angiotensin receptor blocker market are innovating advanced products such as angiotensin receptor neprilysin inhibitors, to increase treatment options and better patient outcomes for cardiovascular diseases. Angiotensin receptor neprilysin inhibitors (ARNIs) represent a category of medicines designed to manage heart failure. For example, Glenmark Pharmaceuticals, a pharmaceutical company based in India, debuted sacubitril + valsartan tablets in January 2023. These tablets are specifically made to treat heart failure, with a particular focus on heart failure with reduced ejection fraction (HFrEF). This product blend is part of the ARNI (angiotensin receptor neprilysin inhibitors) medication class. Sacubitril boosts the natriuretic peptide (NP) system, which helps in reducing fluid overload and supporting blood vessel expansion, while valsartan inhibits the renin-angiotensin system (RAS), reducing blood pressure and lightening the load on the heart. Collectively, they enhance heart failure symptoms management, decrease the likelihood of cardiovascular death, and lower the risk of hospital admissions related to heart failure. These tablets are sold under the Sacu V brand name.
What Are The Most Active Companies In The Angiotensin Receptor Blockers (ARBs) Market Today?
Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma
Get The Full Report Here:
Which Regional Markets Are Attracting The Most Investment In Angiotensin Receptor Blockers (ARBs)?
North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
